{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-25-000009","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.419163+00:00","generated_at":"2026-05-24T03:57:16.015315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Shattuck Labs Q4 2024 net loss $18.7M; advances SL-325 DR3 antibody to Phase 1","bullets":["Cash and investments $73.0M as of Dec 31, 2024; expected to fund operations into 2027.","Net loss Q4 2024 $18.7M ($0.37/share) vs $17.7M ($0.41) Q4 2023; FY loss $75.4M vs $87.3M.","R&D expenses $15.4M Q4; full year $67.2M down from $74.3M due to termination of SL-172154 program.","SL-325 DR3 blocking antibody on track for IND filing in Q3 2025; Phase 1 enrollment expected complete Q2 2026.","Preclinical NHP data at ECCO showed favorable safety, full receptor occupancy, no DR3 agonism."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-25-000009","json":"https://secwatch.observer/filing/0001680367-25-000009.json","markdown":"https://secwatch.observer/filing/0001680367-25-000009.md","text":"https://secwatch.observer/filing/0001680367-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000009/0001680367-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000009/sttk-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:57:16.015315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}